Chronic News and Research

RSS

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT).

25 Apr 2015

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.

25 Apr 2015

Hartford Foundation grant to support evaluation of long-term nursing home resident care model

Approximately 1.4 million older adults in America live in nursing homes. A new grant from the John A. Hartford Foundation will enable clinician-researchers from the Indiana University Center for Aging Research and the Regenstrief Institute and their partners, to prepare for the expansion of OPTIMISTIC, their long-term nursing home resident care model.

25 Apr 2015

Record number of abstracts submitted to Heart Failure 2015

A record number of abstracts have been submitted to the world's leading heart failure congress, promising more original science than ever before.

25 Apr 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).

25 Apr 2015

PCMH care model gaining acceptance in primary care, specialist practices

Primary-care physicians play a pivotal role in assuring that patients who require specialized care are transitioned properly from one clinical environment to another to help lower the risks for adverse events and repeat hospitalizations, according to a health quality management expert who spoke today at the National Quality Summit sponsored by the National Association for Healthcare Quality.

25 Apr 2015

New study shows 'alarming rise' in costs of MS drugs over last 20 years

A new study shows an "alarming rise" over the last 20 years in the costs of drugs used to slow the progression of multiple sclerosis or reduce the frequency of attacks, according to a study led by researchers at Oregon Health & Science University and Oregon State University.

25 Apr 2015

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.

25 Apr 2015

UTMB study highlights current use of oxygen therapy in patents with COPD

A new study about the use of oxygen to treat chronic obstructive pulmonary disease from The University of Texas Medical Branch at Galveston found that the majority of patients receiving oxygen therapy were low-income, non-Hispanic white females about 75 years old with two or more other health conditions.

24 Apr 2015

Bacterial imbalance in the gut can lead to inflammation similar to Crohn's disease

Crohn's disease is one of a family of chronic inflammatory bowel diseases (IBD). While it has already been proven to have genetic causes, scientists have now shown that the presence of certain intestinal bacteria also plays a role.

24 Apr 2015

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia.

24 Apr 2015

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service (DATIS) based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia.

24 Apr 2015

First CE marked FGF23 ELISA assay launched at Biomedica Immunoassays

The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease - mineral and bone disorder (CKD-MBD) in a growing collection.

24 Apr 2015

Cardiff scientists make breakthrough asthma discovery

Cardiff University scientists have for the first time identified the potential root cause of asthma and an existing drug that offers a new treatment.

24 Apr 2015

New research shows that serious life events in childhood can increase type 1 diabetes risk

New research from Sweden published in Diabetologia (the journal of the European Association for the Study of Diabetes) shows that serious life events (SLEs) in childhood, such as death or illness in the family, divorce/separation, a new child or adult in the family, and conflicts in the family, can triple the risk of subsequently developing type 1 diabetes (T1D).

23 Apr 2015

Study highlights need to increase current levels of interventions to reduce HBV transmission

Results revealed today at The International Liver Congress 2015 demonstrate current treatment and prevention programmes need to be scaled up in order to make elimination of hepatitis B virus (HBV) possible.

23 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes.

23 Apr 2015

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Many countries in the World Health Organization European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Chronic News and Research

New data supports use DAAs in patients with HCV recurrence following liver transplantation

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Hartford Foundation grant to support evaluation of long-term nursing home resident care model

Record number of abstracts submitted to Heart Failure 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

PCMH care model gaining acceptance in primary care, specialist practices

New study shows 'alarming rise' in costs of MS drugs over last 20 years

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

UTMB study highlights current use of oxygen therapy in patents with COPD

Bacterial imbalance in the gut can lead to inflammation similar to Crohn's disease

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

First CE marked FGF23 ELISA assay launched at Biomedica Immunoassays

Cardiff scientists make breakthrough asthma discovery

New research shows that serious life events in childhood can increase type 1 diabetes risk

Study highlights need to increase current levels of interventions to reduce HBV transmission

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News